Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04196283
Title A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

hypopharynx cancer

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral squamous cell carcinoma

Therapies

ABBV-368 + IMO-2125

ABBV-368 + IMO-2125 + Nab-paclitaxel

ABBV-181 + ABBV-368 + IMO-2125 + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU


No variant requirements are available.